When do I choose omeprazole and when famotidine? Review article
Article Sidebar
Published:
Nov 30, 2025
Keywords:
famotidine, omeprazole, gastroesophegal reflux disease, heartburn
Main Article Content
Abstract
The article discusses the most common indications for therapy with omeprazole or famotidine. Particular attention was paid to the profiles of patients with the particular indications for omeprazole versus famotidine.
Article Details
How to Cite
Caban, M., & Małecka-Wojciesko, E. (2025). When do I choose omeprazole and when famotidine?. Medycyna Faktow (J EBM), 18(3(68), 426-428. https://doi.org/10.24292/01.MF.0325.14
Issue
Section
Articles
Copyright by Medical Education. All rights reserved.
References
1. López-Pintor E, Puig-Moltó M, Lumbreras B. EsReflux Protocol: Epidemiological Study of Heartburn and Reflux-like Symptoms in Spanish Community Pharmacies. Int J Environ Res Public Health. 2022; 19: 9807. http://doi.org/10.3390/ijerph19169807.
2. Boura F, Al-Tabakha MM, Hassan N et al. Community pharmacists’ response to complaints of gastroesophageal reflux: A simulated patient study in the Northern United Arab Emirates. PLoS One. 2023; 18: e0279922. http://doi.org/10.1371/journal.pone.0279922.
3. Świdnicka-Siergiejko AK, Marek T, Waśko-Czopnik D et al. Diagnostic and therapeutic management in gastroesophageal reflux disease: consensus of the Polish Society of Gastroenterology. Pol Arch Intern Med. 2022; 132: 16196. http://doi.org/10.20452/pamw.16196.
4. Zubiete-Franco I, Tonks NK. Famotidine increases cellular phospho-tyrosine levels. Biochem Biophys Res Commun. 2024; 734: 150763. http://doi.org/10.1016/j.bbrc.2024.150763.
5. Al Ali HS, Jabbar AS, Neamah NF et al. Long-Term Use of Omeprazole: Effect on Haematological and Biochemical Parameters. Acta Med Indones. 2022; 54: 585-94.
6. Waśko-Czopnik D. 4 profile pacjentów, w leczeniu których wybieram famotydynę. Medycyna Faktów. 2023; 16: 43-5. http://doi.org/10.24292/01.MF.0123.07.
7. Zou S, Ouyang M, Cheng Q et al. Acid-suppressive drugs: A systematic review and network meta-analysis of their nocturnal acid-inhibitory effect. Pharmacotherapy. 2024; 44: 171-83. http://doi.org/10.1002/phar.2899.
8. Sawaid IO, Samson AO. Proton Pump Inhibitors and Cancer Risk: A Comprehensive Review of Epidemiological and Mechanistic Evidence. J Clin Med. 2024; 13: 1970. http://doi.org/10.3390/jcm13071970.
9. McRorie JW, Kirby JA, Miner PB. Histamine2-receptor antagonists: Rapid development of tachyphylaxis with repeat dosing. World J Gastrointest Pharmacol Ther. 2014; 5: 57-62. http://doi.org/10.4292/wjgpt.v5.i2.57.
2. Boura F, Al-Tabakha MM, Hassan N et al. Community pharmacists’ response to complaints of gastroesophageal reflux: A simulated patient study in the Northern United Arab Emirates. PLoS One. 2023; 18: e0279922. http://doi.org/10.1371/journal.pone.0279922.
3. Świdnicka-Siergiejko AK, Marek T, Waśko-Czopnik D et al. Diagnostic and therapeutic management in gastroesophageal reflux disease: consensus of the Polish Society of Gastroenterology. Pol Arch Intern Med. 2022; 132: 16196. http://doi.org/10.20452/pamw.16196.
4. Zubiete-Franco I, Tonks NK. Famotidine increases cellular phospho-tyrosine levels. Biochem Biophys Res Commun. 2024; 734: 150763. http://doi.org/10.1016/j.bbrc.2024.150763.
5. Al Ali HS, Jabbar AS, Neamah NF et al. Long-Term Use of Omeprazole: Effect on Haematological and Biochemical Parameters. Acta Med Indones. 2022; 54: 585-94.
6. Waśko-Czopnik D. 4 profile pacjentów, w leczeniu których wybieram famotydynę. Medycyna Faktów. 2023; 16: 43-5. http://doi.org/10.24292/01.MF.0123.07.
7. Zou S, Ouyang M, Cheng Q et al. Acid-suppressive drugs: A systematic review and network meta-analysis of their nocturnal acid-inhibitory effect. Pharmacotherapy. 2024; 44: 171-83. http://doi.org/10.1002/phar.2899.
8. Sawaid IO, Samson AO. Proton Pump Inhibitors and Cancer Risk: A Comprehensive Review of Epidemiological and Mechanistic Evidence. J Clin Med. 2024; 13: 1970. http://doi.org/10.3390/jcm13071970.
9. McRorie JW, Kirby JA, Miner PB. Histamine2-receptor antagonists: Rapid development of tachyphylaxis with repeat dosing. World J Gastrointest Pharmacol Ther. 2014; 5: 57-62. http://doi.org/10.4292/wjgpt.v5.i2.57.